On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Renowned University of Miami Researcher Dr. Giacomo Lanzoni to Speak Tonight, Courtesy of the AASCP
Dr. Giacomo Lanzoni to speak on a live webcast hosted tonight, Wednesday, February 3, 2021, courtesy of The American Academy of Stem Cell Physicians!
The American Academy of Stem Cell Physicians (AASCP) offers various events tailored for doctors and the research community. It is constantly keeping up with the latest developments in regenerative medicine, including diagnosis, treatments, and prevention of diseases. In an exciting webcast to be held tonight, Wednesday, February 3, 2021, the AASCP will feature renowned researcher, Dr. Giacomo Lanzoni. [Read more…]
LifePlus Stem Cells Delivers its First Allogeneic Mesenchymal Stem Cells for the Treatment of Arthritis
LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.
New Lab at UF’s Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
Noninvasive cellular and acellular therapies will lead to life-extending medicines and treatments, including post-COVID anti-inflammation therapy. A new partnership between the world’s top university for biotech business incubation and Neobiosis, a global expert in regenerative medicine, may fuel a healthcare revolution.
Alachua, FLA., January 19, 2021 – The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA “Post-COVID Syndrome”) will be one of many focuses of a new Research & Development laboratory recently launched at the University of Florida Sid Martin Innovate Biotechnology Institute, the world-recognized leader in biotechnology incubation(1). Neobiosis, which produces regenerative tissues, cells and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate the laboratory at the biotech center, located in Alachua, Fla. [Read more…]
Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 123
- Next Page »